Kling Biotherapeutics Strengthens Leadership Team to Advance Pipeline Using its Proprietary Primary B-Cell Selection and Evolution Platform

10.12.24Kling Biotherapeutics Strengthens Leadership Team to Advance Pipeline Using its Proprietary Primary B-Cell Selection and Evolution Platform
31.10.24Kling Biotherapeutics to Present Key Applications for its Primary B-Cell Immortalization, Screening and Antibody Optimization Platform Technologies at PEGS Europe
22.02.24Kling Biotherapeutics to Present Discoveries on its Primary B-Cell Screening Platform at the ESMO Targeted Anticancer Therapies Congress
05.12.23Kling Bio Announces Appointment of Dr Stefano Gullà as Chief Scientific Officer
12.12.22Kling Biotherapeutics Appoints Michael Koslowski, M.D. As Chief Executive Officer
29.09.22Kling Biotherapeutics Announces First Patient Dosed in Phase 1b Clinical trial of KBA1412 in Patients with Advanced Solid Tumors